Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

CEOs are getting ruthless about worker performance

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volume growth, positive mix, consistent growth margin expansion." This shift towards "performance cultures" involves tougher accountability, potential layoffs, and a focus on tangible outcomes, signaling a departure from the more empathetic approach of the…

The Economic Times

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter. Narasimham said the company’s und

Omeros Q1 Earnings Call Highlights

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive

Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

inkl

Read news from The Economist, FT, and more,
with one subscription

Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy

Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy

Last October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development ‌of ⁠the therapy.

The Economic Times

Novo Nordisk boosted as sales of Wegovy weight loss pills soar

Novo Nordisk boosted as sales of Wegovy weight loss pills soar

The Independent UK

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

Evening Standard

Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly

The Independent UK

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

Hershey's CEO Claims Ozempic Breath is Driving Massive Surge in Mint and Gum Sales Across the United States

Hershey's CEO Claims Ozempic Breath is Driving Massive Surge in Mint and Gum Sales Across the United States

Hershey's CEO attributes an 8% sales increase in Ice Breakers mints and gum to the side effects of GLP-1 weight-loss drugs, highlighting an unexpected revenue driver.

International Business Times UK

Trump team delays pilot program for Medicare to cover cost of ‘fat shot’

Trump team delays pilot program for Medicare to cover cost of ‘fat shot’

Without insurance or discounts, GLP-1 injectables can cost more than $1,000 per month

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.

What to know about OpenAI's new model for life sciences research GPT-Rosalind

The GPT-Rosalind model is designed to accelerate biological research and drug discovery.

The Independent UK

FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be linked to liver, heart and gastrointestinal problems

The Independent UK

Wegovy maker announces partnership with OpenAI

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Wegovy maker and OpenAI partnering to speed up search for new drugs

The Danish drug manufacturer announced the partnership Tuesday, noting that the goal was to bring ‘new and better treatment options to patients faster’

Novo Nordisk joins forces with OpenAI to fast-track drug research

Danish pharma company Novo Nordisk has announced a partnership with OpenAI to apply artificial intelligence across its drug development process.

The Independent UK

Trump sets 100% tariffs on prescription drugs from companies that have not reached a deal with him to lower prices

The tariffs were announced on the anniversary of Trump’s ‘Liberation Day,’ which saw U.S. trading partners hit with sweeping levies

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

The Independent UK

Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable

The Independent UK

Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs

A bipartisan group of senators is aiming to relieve high insulin costs for more Americans

The Guardian - US

US approves new oral weight-loss pill developed by Eli Lilly

Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy

1 2 3 4 5

People

189,567 stories

Mark Zuckerberg

Philipp Navratil

Fernando Fernandez

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Independent

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

373,928 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play